Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Ruben Mesa, MD, FACP; Andrew Kuykendall, MD; and Sangeetha Venugopal, MD, MS; discuss evolving management strategies for patients with MF, and considerations for selecting therapy based on patient-related and disease-related factors.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate recent clinical trial data for new and emerging strategies to treat patients with MF
• Integrate appropriate evidence-based treatment strategies for patients with newly diagnosed and previously treated MF
• Examine best practices and clinical considerations for supportive care in MF

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from Bristol Myers Squibb and PharmaEssentia.

Faculty:

Ruben A. Mesa, MD, FACP

President, Advocate Health Cancer National Service Line
President, Atrium Health Levine Cancer
Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Senior Vice President, Advocate Health
Vice Dean for Cancer Programs, Wake Forest University School of Medicine
The Charles L. Spurr MD Professor of Medicine, Wake Forest University School of Medicine
Winston-Salem, NC

Disclosures: Advisor, Consultant, Fee for Service Recipient: Blueprint, BMS, Disc, Genentech, GSK, Incyte, Novartis, PharmaEssentia, Sobi, Takeda; Grant/Research Funding: Incyte, PharmaEssentia

Andrew Kuykendall, MD

Assistant Member
Moffitt Cancer Center
Tampa, FL

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Agis, Blueprint, Calytrix, Cellgate, Cogent, Deciphera, Geron, Incyte, Karyopharm, Merck, Opna, PharmaEssentia, Protagonist, Silence, Sobi, Takeda; Grant/Research Funding: Ajax, BMS, Blueprint, Geron, Incyte, Janssen, Kartos, MorphoSys, Novartis, Protagonist

Sangeetha Venugopal, MD, MS

Assistant Professor of Medicine
Leukemia Program, Division of Hematology
Sylvester Comprehensive Cancer Center
University of Miami Leonard M. Miller School of Medicine
Miami, FL

Disclosures: Advisory Board: Sobi; Grant/Research Funding (paid to institution): Oryzon Pharmaceuticals

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including considerations related to the diagnosis of MF and additional perspectives on selecting therapy, go to https://www.gotoper.com/courses/cases-and-conversations-applying-the-evidence-real-world-strategies-to-optimize-care-for-patients-with-myelofibrosis-jadn.

Release Date

July 17, 2026

Expiration Date

July 17, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.